High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia.
dc.contributor.affiliation | Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland. | |
dc.contributor.affiliation | Division of Infectious Diseases, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA. | |
dc.contributor.affiliation | Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, South Africa. | |
dc.contributor.affiliation | Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA. | |
dc.contributor.affiliation | Liver Center and Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. | |
dc.contributor.affiliation | Ministry of Health, Lusaka, Zambia. | |
dc.contributor.affiliation | School of Medicine, University of Zambia, Lusaka, Zambia. | |
dc.contributor.affiliation | Institute of Social and Preventative Medicine, University of Bern, Bern, Switzerland. | |
dc.contributor.affiliation | Centre for Infectious Disease Research in Zambia, Lusaka, Zambia. | |
dc.contributor.affiliation | CIDRZ | |
dc.contributor.affiliation | Centre for Infectious Disease Research in Zambia (CIDRZ) | |
dc.contributor.author | Chihota BV | |
dc.contributor.author | Wandeler G | |
dc.contributor.author | Chilengi R | |
dc.contributor.author | Mulenga L | |
dc.contributor.author | Chung RT | |
dc.contributor.author | Bhattacharya D | |
dc.contributor.author | Egger M | |
dc.contributor.author | Vinikoor MJ | |
dc.date.accessioned | 2025-05-23T11:41:18Z | |
dc.date.issued | 2020-Jan-02 | |
dc.description.abstract | Among 284 human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfected adults starting tenofovir-based antiretroviral therapy (ART) in Zambia, median baseline CD4+ count was 202 cells/mm3 and 41.6% were hepatitis B e-antigen positive. Within 2 years of therapy, 29 (10.2%) participants experienced HBV functional cure (confirmed loss of hepatitis B surface antigen). In multivariable analysis, baseline CD4 count <350 cells/mm3, female sex, and lower baseline HBV deoxyribonucleic acid were associated with increased odds of functional cure. Immune recovery during HIV-HBV treatment with ART may drive higher rates of functional cure than during HBV monoinfection treatment. Understanding the mechanisms underlying this phenomenon could inform immunomodulatory therapies for HBV cure. | |
dc.identifier.doi | 10.1093/infdis/jiz450 | |
dc.identifier.uri | https://pubs.cidrz.org/handle/123456789/10448 | |
dc.source | The Journal of infectious diseases | |
dc.title | High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia. |